Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of Alisma plantago-aquatica Linn extract on hyperprolactinemia in rats

Ming Wen, De-ming Tian, Shao-feng Shi, Xin-hua Chen, Yan-xiang Zhang, Lin Wang

Department of Obstetrics and Gynecology, The First People's Hospital of Wuhu City, Wuhu 241000, Anhui, China;

For correspondence:- Lin Wang Email: wangling494@126.com Tel:+865532676321

Accepted: 27 May 2019 Published: 30 June 2019

Citation: Wen M, Tian D, Shi S, Chen X, Zhang Y, Wang L. Effect of Alisma plantago-aquatica Linn extract on hyperprolactinemia in rats. Trop J Pharm Res 2019; 18(6):1273-1276 doi: 10.4314/tjpr.v18i6.18

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the anti-hyperprolactinemia effect and mechanism of action of of Alisma plantago-aquatica Linn. extract (APLE) in rats.

Methods: The hyperprolactinemia (hyperPRL) model of rats was established by intraperitoneal (i.p.) metoclopramide (200 mg/kg daily) for 10 days. Sixty rats were divided into six groups (n = 10 each): normal group), hyperPRL control group, hyperPRL plus 0.6 mg/kg bromocriptine (as a positive control) group, and hyperPRL plus high (14.4 g/kg), medium (7.2 g/kg), or low (3.6 g/kg) dose of APLE. Bromocriptine or vehicle control was administered to the rats daily for 30 days, and the hypothalamus dopamine D2 receptor, protein kinase A (PKA), and cyclic adenosine monophosphate (cAMP) levels were investigated by Western blot.

Results: Compared with the normal rats, hypothalamus dopamine D2 receptor protein expression was significantly lower in hyperPRL rats (p < 0.01), but was changed significantly after 30-day doses (various) of APLE administration (3.6 g/kg, p < 0.05; 7.2 and 14.4 g/kg, p < 0.01). Compared with the control rats, hypothalamus PKA and cAMP levels were significantly higher in hyperPRL rats (p < 0.01). These increases in PKA and cAMP were significantly attenuated by 30-day of bromocriptine treatment or various doses of APLE (p < 0.01).

Conclusion: The anti-hyperPRL activity of APLE is confirmed from the findings of this study Thus, the plant can potentially be developed into a new anti-hyperprolactinemia drug.

Keywords: Hyperprolactinemia, Dopamine D2 receptor, cAMP/PKA, Alisma plantago-aquatica